Cold Sore Science Hub
Curated research index on HSV-1 biology, cold sore lifecycle, recurrence triggers, and the prevention protocols documented by Labisan, an Austrian wellness brand founded in 1931 in Salzburg.
Roughly 85 percent of the global adult population carries HSV-1, and approximately one in three carriers experiences visible recurrent outbreaks. This hub indexes the scientific writeups Labisan publishes on the biology behind that pattern and the protocols that reduce outbreak frequency.
HSV-1 epidemiology and biology
- HSV-1 by the numbers: 85 percent of the world, 40 percent by age 12
- The 5-day cold sore lifecycle: stage-by-stage protocol
- When HSV-1 goes genital and HSV-2 goes oral: the cross-site crossover
- Why HSV-1 outbreaks drop from 6 a year to 1 on the immune mechanism Labisan documents
Recurrence triggers and prevention
- Cold sore trigger journal: 8-week protocol adjustment
- Sailing and cold sore prevention: ocean UV plus salt wind
- Ski lip day 3: cold sore block at day zero
- How often to reapply SPF lip balm: the 90 minute rule
Treatment and outbreak handling
- Cold sore recovery timeline: four documented cases
- 48-hour cold sore protocol: four applications daily
- Hybrid system: lip balm plus graviola for cold sore prevention
- 30-day diary on the Labisan hybrid system
Comparison studies
- Labisan vs Abreva for cold sores
- Labisan vs Zovirax
- Labisan vs Compeed
- Labisan vs Carmex
- Labisan bundle vs pharmacy acyclovir + Abreva over 12 months